Down-regulation of telomerase activity and activation of caspase-3 are responsible for Tanshinone I-induced apoptosis in monocyte leukemia cells in Vitro

International Journal of Molecular Sciences

Volumn 11, Issue 6, 2010, Pages 2267-2280

  Liu, Xiao Dan ^a   Fan, Rui Fang ^a   Zhang, Yong ^a   Yang, Hong Zhi ^a   Fang, Zhi Gang ^a   Guan, Wei Bing ^a   Lin, Dong Jun ^a   Xiao, Ruo Zhi ^a   Huang, Ren Wei ^a   Huang, He Qing ^b   Liu, Pei Qing ^b   Liu, Jia Jun ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Leukemia; Survivin; Tanshinone I (Tan I); Telomerase

Indexed keywords

CASPASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SURVIVIN; TANSHINONE I; TELOMERASE REVERSE TRANSCRIPTASE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; MOLECULAR WEIGHT; MONOCYTE; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

LEUKEMIA; SURVIVIN; TANSHINONE I (TAN-I); TELOMERASE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; DITERPENES, ABIETANE; DOWN-REGULATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; TELOMERASE; U937 CELLS;

SALVIA MILTIORRHIZA;

EID: 77954771133     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms11062267     Document Type: Article

References (23)

1. Boon, H.; Wong, J. Botanical medicine and cancer: A review of the safety and efficacy. Exp. Opin. Pharmacother. 2004, 5, 2485-2501.
2. Zhou, L.; Zuo, Z.; Chow, M.S. Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J. Clin. Pharmacol. 2005, 45, 1345-1359.
3. Wang, A.M.; Sha, S.H.; Lesniak, W.; Schacht, J. Tanshinone (Salviae miltiorrhizae extract) preparations attenuate aminoglycoside-induced free radical formation in vitro and ototoxicity in vivo. Antimicrob. Agents Chemother. 2003, 47, 1836-1841.
4. Xu, W.X.; Li, J.F.; Dong, C. Spectral Properties of Tanshinone I and pH Effect on Its Molecular Structure. Chin. J. Spectro. Lab. 2003, 20, 319-323.
5. Su, C.C.; Chen, G.W.; Lin, J.G. Growth inhibition and apoptosis induction by tanshinone I in human colon cancer Colo 205 cells. Int. J. Mol. Med. 2008, 22, 613-618.
6. Lee, C.Y.; Sher, H.F.; Chen, H.W.; Liu, C.C.; Chen, C.H.; Lin, C.S.; Yang, P.C.; Tsay, H.S.; Chen, J.J. Anticancer effects of tanshinone I in human non-small cell lung cancer. Mol. Cancer Ther. 2008, 7, 3527-3538.
7. Nizamutdinova, I.T.; Lee, G.W.; Son, K.H.; Jeon. S.J.; Kang, S.S.; Kim, Y.S.; Lee, J.H.; Seo, H.G.; Chang, K.C.; Kim, H.J. Tanshinone I effectively induces apoptosis in estrogen receptor-positive (MCF-7) and estrogen receptor-negative (MDA-MB-231) breast cancer cells. Int. J. Oncol. 2008, 33, 485-491.
8. Debatin, K.M. Apoptosis pathways in cancer and cancer therapy. Cancer. Immunol. Immunother. 2004, 53, 153-197.
9. Rossi, D.; Gaidano, G. Messengers of cell death: apoptotic signaling in health and disease. Haematologica. 2003, 88, 212-218.
10. Tsuruo, T.; Naito, M.; Tomida, A.; Fujita, N.; Mashima, T.; Sakamoto, H.; Haga, N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci. 2003, 94, 15-21.
11. Ryan, B.M.; O'Donovan, N.; Duffy, M.J. Survivin: A new target for anti-cancer therapy. Cancer Treat Rev. 2009, 35, 553-562.
12. Kanwa, R.K.; Cheung, C.H.; Chang, J.Y.; Kanwar, J.R. Recent advances in anti-survivin treatments for cancer. Curr. Med. Chem. 2010, 17, 1509-1515.
13. Oto, O.A.; Paydas, S.; Tanriverdi, K.; Seydaoglu, G.; Yavuz, S.; Disel, U. Survivin and EPR-1 expression in acute leukemias: prognostic significance and review of the literature. Leuk. Res. 2007, 31, 1495-1501.
14. Lin, K.W.; Yan, J. The telomere length dynamic and methods of its assessment. J. Cell Mol. Med. 2005, 9, 977-989.
15. Parkinson, E.K. Telomerase as a novel and potentially selective target for cancer chemotherapy. Ann. Med. 2003, 35, 466-475.
16. Mokbel, K. The evolving role of telomerase inhibitors in the treatment of cancer. Curr. Med. Res. Opin. 2003, 19, 470-472.
17. Cosme-Blanco, W.; Chang, S. Dual roles of telomere dysfunction in initiation and suppression of tumorigenesis. Exp. Cell Res. 2008, 314, 1973-1979
18. Tauchi, T.; Shin-ya, K.; Sashida, G.; Sumi, M.; Okabe, S.; Ohyashiki, J.H.; Ohyashiki, K. Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: In vitro and in vivo studies in acute leukemia. Oncogene 2006, 25, 5719-5725.
19. Nakajima, A.; Tauchi, T.; Sashida, G.; Sumi, M.; Abe, K.; Yamamoto, K.; Ohyashiki, J.H.; Ohyashiki, K. Telomerase inhibition enhances apoptosis in human acute leukemia cells: Possibility of antitelomerase therapy. Leukemia 2003, 17, 560-567.
20. Shammas, M.A.; Koley, H.; Bertheau, R.C.; Neri, P.; Fulciniti, M.; Tassone, P.; Blotta, S.; Protopopov, A.; Mitsiades, C.; Batchu, R.B.; Anderson, K.C.; Chin, A.; Gryaznov, S.; Munshi, N.C. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia 2008, 22, 1410-1418.
21. Parsch, D.; Brassat, U.; Brummendorf, T.H.; Fellenberg, J. Consequences of telomerase inhibition by BIBR1532 on proliferation and chemosensitivity of chondrosarcoma cell lines. Cancer Invest. 2008, 26, 590-596.
22. Yang, S.M.; Fang, D.C.; Yang, J.L.; Chen, L.; Luo, Y.H.; Liang, G.P. Antisense human telomerase reverse transcriptase could partially reverse malignant phenotypes of gastric carcinoma cell line in vitro. Eur. J. Cancer Prev. 2008, 17, 209-217.
23. Moorhouse, A.D.; Haider, S.; Gunaratnam, M.; Munnur, D.; Neidle, S.; Moses, J.E. Targeting telomerase and telomeres: A click chemistry approach towards highly selective G-quadruplex ligands. Mol. Biosyst. 2008, 4, 629-642.